KARYOPHARM THERAPEUTICS INC. overview

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Jan. 2, 2025 NEWTON, Mass. , Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 101,250 shares of Karyopharm's common stock and an aggregate of 108,540 restricted stock units (RSUs) to four newly-hired...

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer PR Newswire NEWTON, Mass., Jan. 2, 2025 NEWTON, Mass. , Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025 . In this role, Ms. Macomber will be responsible for leading and...

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications PR Newswire NEWTON, Mass., Dec. 9, 2024 NEWTON, Mass. , Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on...

Karyopharm Therapeutics Provides Endometrial Cancer Program Update PR Newswire NEWTON, Mass., Dec. 3, 2024 NEWTON, Mass. , Dec. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Dec. 2, 2024 NEWTON, Mass. , Dec. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 4,800 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of November 30, 2024 (the "Grant Date") pursuant...

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference PR Newswire NEWTON, Mass., Nov. 25, 2024 NEWTON, Mass. , Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36 th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY . A...

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer PR Newswire NEWTON, Mass., Nov. 20, 2024 NEWTON, Mass. , Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate , the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant...

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire NEWTON, Mass., Nov. 5, 2024 – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $29.5 Million ; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve...